GlassScriptPhysician profile
Barry W Sigal
NPI 1316929102
$2,065.02
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $669 · 2020: $1,066 · 2021: $297 · 2022: $16.53 · 2023: $16.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $715.67 | 2020 | |
| La Jolla Pharmaceutical Company | $246.32 | 2019-2020 | |
| Glaxosmithkline, LLC. | $219.67 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.29 | 2019-2021 | |
| Csl Behring | $66.05 | 2019-2021 | |
| Grifols USA, LLC | $61.60 | 2020-2021 | |
| Gilead Sciences, INC. | $52.83 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $50.16 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $45.63 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $44.51 | 2020-2021 | |
| Philips North America LLC | $39.69 | 2020 | |
| Alexion Pharmaceuticals, INC. | $38.99 | 2019-2020 | |
| Pfizer INC. | $37.05 | 2019 | |
| Bio Products Laboratory USA, INC. | $34.69 | 2019 | |
| Insmed, INC. | $28.13 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $27.85 | 2019-2021 | |
| Covis Pharma Gmbh | $26.20 | 2021 | |
| Mylan Specialty L.P. | $25.94 | 2019-2021 | |
| Genzyme Corporation | $24.83 | 2019 | |
| United Therapeutics Corporation | $21.10 | 2020 | |
| Mallinckrodt Enterprises LLC | $18.57 | 2019 | |
| Electromed, INC. | $16.66 | 2021 | |
| Jazz Pharmaceuticals INC. | $14.21 | 2021 | |
| Merck Sharp & Dohme LLC | $13.44 | 2019 | |
| Hospira, INC. | $13.37 | 2021 | |
| Allergan, INC. | $13.32 | 2020 | |
| Phadia US INC. | $12.67 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.58 | 2021 |
11 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Sigal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.